Ketamine for OCD: What Research Shows and What Is Still Unclear
When intrusive thoughts and rituals keep returning despite treatment, it is understandable to look for a different approach. Research on ketamine for OCD offers a reason for scientific interest, but not a reason to assume that it is an established solution. Small controlled studies have reported short-term symptom improvement in some adults. Important questions about lasting benefit, repeat treatment, and patient selection remain unresolved.
Ketamine is not FDA-approved to treat obsessive-compulsive disorder. Spravato, the prescription esketamine nasal spray, is a different product with specific depression indications—not an OCD approval. Understanding that distinction helps you assess an unfamiliar treatment without dismissing either its potential or its limitations.
Why are researchers studying ketamine for OCD?
OCD involves unwanted, recurring thoughts or urges and compulsions performed to reduce distress. Compulsions can be visible, such as checking, or mental, such as repeatedly reviewing a memory. The question is not simply whether a person feels less anxious during an appointment. It is whether treatment reduces the time, distress, avoidance, and disruption associated with these patterns.
Ketamine interacts with the NMDA receptor, part of the brain’s glutamate signaling system. Researchers have investigated whether this different biological target could help people whose symptoms have not improved sufficiently with established care. That research does not prove that OCD is caused by one chemical imbalance, or that ketamine repairs a specific defect in every patient.
It also does not establish that findings about depression automatically apply to obsessions and compulsions. These are different clinical outcomes and need to be measured separately.
Does ketamine work for OCD? What studies found
How long does ketamine last for OCD? What the early trial suggests
A 2013 randomized proof-of-concept study enrolled 15 medication-free adults with near-constant obsessions. Because effects carried over between study periods, the researchers focused subsequent analyses on the first period. One week after treatment, four of the eight participants initially receiving intravenous ketamine met the study’s OCD response threshold, compared with none of seven receiving saline.
That result is encouraging, but “four people improved” is not a reliable prediction that half of all patients will improve. The sample was small and selected, and the study did not establish a durable treatment plan for the broader OCD population.
Watch the video: Toward Rapid-Acting Treatments for OCD (Brain & Behavior Research Foundation)
A more recent study still leaves important questions
A controlled study published in the 2025 journal volume compared intramuscular ketamine with an active control in treatment-resistant OCD. Twelve participants were randomized and ten completed the study. OCD symptom reductions favored ketamine, while two participants discontinued because they could not tolerate dissociative effects. Follow-up assessed changes over approximately one week.
The study adds to the evidence, but its size and short follow-up still limit conclusions. Different routes, doses, patient histories, and comparison treatments also mean that the studies should not be combined into a single advertised “success rate.”
These trials support further investigation. They do not answer every question about who should receive treatment, how often it should be repeated, or how long improvement will last.
OCD improvement and depression improvement are not the same
Someone can have both OCD and depression. Feeling less hopeless or having more energy would be meaningful, even if compulsions remained largely unchanged. Conversely, a reduction in time spent checking would be important even if mood needed additional treatment.
A useful evaluation therefore tracks both experiences. For example, a hypothetical patient might report less emotional distress but still spend two hours each evening reviewing conversations. That is different from a sustained reduction in the reviewing itself. Neither change should be ignored, but they should not be mislabeled.
When discussing research, ask what improved: overall depression scores, obsessive thoughts, compulsive behavior, functioning, or several of these. Also ask whether the improvement lasted beyond the immediate medication effects. Temporary detachment during treatment is not, by itself, proof of recovery from OCD.
Why established OCD treatment still matters
The National Institute of Mental Health’s OCD guidance describes medication and psychotherapy, including exposure and response prevention, as treatment options. Exposure and response prevention, often called ERP, helps people face triggers while learning not to respond with compulsions. It is not simply reassurance, general stress management, or being told to confront a fear without support.
Before labeling OCD “treatment-resistant,” a clinician may review what treatments were actually tried, whether therapy specifically targeted OCD, medication duration and tolerability, and other conditions affecting progress. A treatment that was stopped early because of adverse effects raises a different question from a full treatment course that brought little benefit.
Do not stop medication or abandon established therapy to pursue an emerging option on your own. A specialist discussion can consider optimization, alternative established treatments, or a research study without treating any one intervention as the inevitable next step.
Ketamine therapy for OCD: risks and uncertainties
The FDA’s ketamine safety and approval warning distinguishes approved products from unapproved psychiatric claims and emphasizes significant risks. Ketamine-related care requires attention to sedation, changes in perception, breathing, blood pressure, and the potential for misuse. Product, route, and clinical setting matter.
Ask how the proposed service evaluates medical and psychiatric history, reviews other substances and medications, monitors patients, handles a concerning reaction, and coordinates follow-up. “Medical treatment” should describe an accountable process, not just the presence of a prescription.
A clinic should also explain the evidence relevant to the exact treatment being offered. An intravenous study does not establish identical outcomes for a compounded nasal spray or a take-home product. Paying privately does not turn a preliminary treatment into an approved one.
Questions to bring to an OCD consultation
Begin with your own goal. Is the main difficulty hours lost to rituals, avoiding family activities, intrusive thoughts, depression, or an inability to engage in therapy? Naming that goal makes it easier to evaluate a proposed plan.
Ask: “What established treatments remain appropriate for me, and have my previous trials been adequate?” Bring medication names, approximate treatment dates, side effects, and the type of psychotherapy you received. Incomplete records are a reason to reconstruct your history, not a reason to feel embarrassed.
Then ask: “What evidence supports this exact intervention for OCD, rather than depression?” Request a clear explanation of approved versus off-label use, likely burdens, uncertainties, and alternatives. A cautious answer is not necessarily a weak answer; it may reflect the limits of the evidence honestly.
Finally, ask how improvement and continuation will be assessed. A plan should identify what will be measured and when treatment will be reconsidered if benefits are insufficient. Consider transport, time away from work, follow-up access, and total cost alongside the clinical discussion.
Getting help through Sophroneo
Sophroneo Behavioral Health & TMS provides OCD-related care and therapy and counseling. An assessment can help clarify your symptoms and the next appropriate step; it should not begin with an assumption that you need ketamine.
For people with co-occurring mood symptoms, depression care can be discussed alongside the OCD treatment plan. Sophroneo has locations in Powder Springs and Marietta, serving the Atlanta area. Contact the practice to discuss an evaluation and confirm which services are appropriate and available. This article does not imply that Sophroneo offers ketamine specifically for OCD.
Frequently asked questions
Is Spravato approved for OCD?
No. The current Spravato prescribing information lists specific adult depression indications, not OCD. Having both depression and OCD does not mean that an approved depression treatment is also an approved OCD treatment.
Does a strong reaction during treatment mean it is working?
Not necessarily. A noticeable medication experience is different from a sustained reduction in obsessions, compulsions, or impairment. The relevant question is how symptoms and daily life change over time, assessed with your clinician—not how intense the appointment feels.
Can ketamine replace exposure and response prevention?
The small studies discussed here do not establish it as a replacement for ERP. Treatment decisions should consider your history, access to OCD-specific care, preferences, risks, and the evidence for each option. Do not change an existing plan without discussing it with your treating clinician.
This article is educational and does not provide a diagnosis or individualized treatment advice. If you are in emotional crisis in the United States, call or text 988. For immediate danger or a life-threatening emergency, call 911.
Comments